Shares of a small-cap biotech newcomer soared to a record high. What inspired investors?
Shares of BlossomHill Therapeutics, a newcomer to the stock market, soared following the release of new clinical data / Photo: LinkedIn / Nasdaq Exchange
Shares of BlossomHill Therapeutics, a newcomer to the stock market that went public on Nasdaq just over a month ago, soared more than 18% on September 16—reaching an all-time high. The company reported that new clinical data indicate the effectiveness of its experimental drug in patients with mutated lung cancer, a condition that causes the tumor to stop responding to treatment.
Details
BlossomHill shares rose more than 18% on the Nasdaq on September 16, reaching $26.25. This is the highest price in the company's history.
The rally was triggered by the release of new clinical data on the efficacy and safety of the company’s experimental drug, BH-30643. The company tested it on patients with non-small-cell lung cancer whose tumors had mutated as a result of treatment and had become resistant to therapy. According to a press release, there are no approved targeted therapies (i.e., therapies that strike directly at the target rather than affecting the entire body, as chemotherapy does) for people with this condition.
Its development is currently in the early stages of testing. However, the data obtained and the fact that the U.S. regulatory agency has granted BH-30643 “fast-track” status (which grants priority based on its potential value to patients), will allow it to advance to mid-stage clinical trials in 2027, according to a press release.
What Is Known About the Company
BlossomHill focuses on developing drugs for cancer therapy. In addition to BH-30643, its portfolio includes two other molecules. One is also in the early stages of clinical trials and is intended to treat acute myeloid leukemia, a cancer of the blood and bone marrow. The second—for solid tumors (those with dense tissue)—has not yet progressed to human trials.
While the company is not yet generating revenue from its operations, its net loss nearly doubled to $60.6 million by the end of 2025, according to its IPO prospectus.
The biotech company held its initial public offering on the Nasdaq in early August, offering investors 9.37 million shares—more than the company had originally planned —at $16 each.
Since then, its share price has soared 64%.
Five Wall Street analysts are tracking BlossomHill, and all unanimously recommend buying its stock. The average price target is $32.2, which is nearly 23% higher than the most recent closing price.
